

# XPhyto Therapeutics Corp.

09:15 06 Jul 2020

## XPhyto Therapeutics says COVID-19 rapid screening test prototype achieves validation

XPhyto Therapeutics Corp (CSE:XPHY) (FSE:4XT) (OTCPINK:XPHYF) said Monday that its diagnostic partner, 3a-Diagnostics GmbH, has confirmed the successful working of its novel COVID-19 RNA probes and its universal coronavirus RNA probes in a prototype of a lateral flow assay (LFA) test.

Prototype testing was carried out at 3a's lab in Baden-Württemberg, Germany. Vancouver-based XPhyto said that "visual confirmation of the test results" with probe activation was observed in "five to seven minutes."

XPhyto and 3a are working to develop a low-cost oral screening test to concurrently detect COVID-19 and non-COVID-19 coronaviruses.

READ: XPhyto Therapeutics says diagnostic partner confirms active functionality of peptide biosensors incorporated into its oral dissolvable thin film platform

3a is focused on detecting viruses during the early stages when patients are highly contagious and often asymptomatic.

The LFA test is designed for saliva samples and is also expected to function effectively using test solutions from throat and nasal swabs.

Prototype testing has confirmed successful activation of both the "COVID-19 specific probes" and the "universal coronavirus probes at viral RNA levels," the company noted.

"We believe that a low-cost, portable and easy to use screening tool that provides rapid on-the-spot results would be a disruptive tool in the fight against pandemic threats," XPhyto Therapeutics CEO Hugh Rogers said in a statement.

"We see an enormous global market opportunity that includes individual households, schools, hospitals, public transportation, airports and border services as well as many private employers," he added.

3a has designed and tested RNA-probes to detect specific viral RNA sequences and provide immediate visual confirmation of the reaction in a prototype LFA screening device. Coronaviruses, like many disease-causing viruses, encode their genome using RNA (not DNA). Two viral RNA probes have been developed: a COVID-19 specific RNA sequence, and a universal coronavirus RNA sequence (shared by all known members of the coronavirus family).

In keeping with the test design, patients infected with COVID-19 are expected to activate the COVID-19 probes and the universal coronavirus probes. On the other hand, patients infected with an alternate coronavirus strain or a highly mutated form of COVID-19 are expected to activate only the universal coronavirus probes.

The company said the "next milestones" are the manufacture of LFA screening tests for use in clinical evaluation, followed by "a pilot study using human saliva from healthy and COVID-19 infected patients." 3a expects to begin the

**Price:** 2.23

**Market Cap:** \$129.36 m

### 1 Year Share Price Graph



November 2019 June 2020 November 20

### Share Information

**Code:** XPHY

**Listing:** CSE

**52 week High Low**  
3.55 0.8

**Sector:** Cannabis

**Website:** www.xphyto.com

### Company Synopsis:

XPhyto Therapeutics Corp.

action@proactiveinvestors.com

pilot study within 30 to 60 days.

Contact the author Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).